Ardena Strengthens Bioanalytical Capabilities with Operational Launch of New Oss Laboratory

Ghent, Belgium, 28^th May 2025

Ardena, a specialist service provider in integrated drug development, today announced a new milestone at its newly established bioanalytical laboratory at Pivot Park in Oss, Netherlands. Following successful commissioning of the facility earlier this year, the site has already initiated several client projects and completed its first sample testing earlier in April. With capabilities tailored to support targeted and innovative therapies, the Oss lab underscores Ardena’s commitment to precision medicine development.

This new facility, purpose-built to support both small and large molecule programs, adds over 3,000 sqft of laboratory space to Ardena’s European bioanalytical network. With extensive experience in developing bioanalytical assays across various matrices and utilizing advanced technologies like state-of-the-art LC-MS/MS systems and immunochemistry platforms (e.g., MSD and Gyrolab), the lab is well-equipped to serve clients across diverse therapeutic modalities and (pre)clinical stages.

The Oss lab complements Ardena’s existing Bioanalytical Center of Excellence in Assen, providing additional capacity, greater operational flexibility, and improved lead times for time-sensitive clinical studies. “We are proud to see the first client programs underway in Oss,” said Gunnar Flik, Division Head of Bioanalytical Services at Ardena. “The lab was built to offer fast, flexible support to biopharma innovators navigating increasingly complex clinical trials. This is a key step in our broader strategy to provide global bioanalytical coverage with local execution.”

The opening of the Oss laboratory follows Ardena’s recent announcement of an upcoming bioanalytical facility in their newly acquired US site in Somerset, NJ. Once operational in Q3 2025, the Somerset lab will mirror Ardena’s European capabilities, further enhancing global clinical trial support and enabling seamless project execution across Europe and North America.

These investments reflect Ardena’s commitment to enabling the development of complex, next-generation therapies. By expanding both geographic reach and scientific capacity, Ardena continues to build a network designed to meet the evolving needs of its clients—across molecules, modalities, and geographies.

About Ardena

Ardena is a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) in precision medicine development of new, innovative, and complex molecules.

Ardena’s mission is to enable current and next-generation therapies to get into the clinic and to patients faster.

Ardena assists biopharmaceutical companies in navigating through the drug discovery and development process, by providing integrated solutions including nanomedicine, drug product and drug substance development and manufacturing, solid-state chemistry, bioanalytical services, and CMC regulatory support.